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Lysophosphatidylcholine (lysoPC) induces vascular 
smooth muscle cell (VSMC) proliferation and migra-
tion, which has been proposed to initiate the intimal 
thickening in coronary atherosclerotic lesions. Berber-
ine is an alkaloid in Berberis aquifolium and many 
other plants. Recently, it has been shown to have bene-
ficial effects on the cardiovascular system, such as 
anti-hyperglycemic and cholesterol-lowering activity. 
In this study, we investigated its effects on lysoPC-
induced VSMC proliferation and migration. Berberine 
inhibited lysoPC-induced DNA synthesis and cell pro-
liferation in VSMCs, as well as migration of the 
lysoPC-stimulated VSMCs. It also inhibited the activa-
tion of extracellular signal-regulated kinases (ERKs) 
and reduced transcription factor AP-1 activity and the 
lysoPC-induced increases in intracellular reactive oxy-
gen species (ROS). These results indicate that the in-
hibitory effects of berberine on lysoPC-stimulated 
VSMC proliferation and migration are attributable to 
inhibition of ROS generation and hence of activation 
of the ERK1/2 pathway. This suggests that berberine 
has potential in the prevention of atherosclerosis and 
restenosis. 
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Introduction 
 
Abnormal proliferation and migration of vascular smooth  
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muscle cells (VSMCs) play a critical role in the develop-
ment of atherosclerosis and restenosis after percutaneous 
coronary angioplasty. Lysophosphatidylcholine (lysoPC), 
a major phospholipid component of low-density lipopro-
teins (LDL), stimulates the proliferation and migration of 
VSMCs (Kohno et al., 1998), and its concentration is 
higher in atherosclerotic arteries than in normal arteries 
(Yla-Herttuala et al., 1989). Recently, it was reported that 
lysoPC-induced ERK1/2 activation is mediated by reac-
tive oxygen species (ROS) (Yamakawa et al., 2002). ROS 
play a key role in inducing VSMC proliferation, which is 
important in the pathogenesis of intimal thickening in 
atherosclerosis and restenosis (Chen et al., 2003). ROS 
generation has been shown to be related to the activation 
of mitogen-activated protein (MAP) kinases and transcrip-
tion factors, such as activator protein-1 (AP-1) (Han et al., 
2003; Martindale and Holbrook, 2002). LysoPC potenti-
ates vascular contractile responses in the rat aorta by acti-
vating ERK (Suenaga and Kamata, 2003). Consequently, 
lysoPC-induced MAP kinase activation in VSMCs could 
be involved in the pathogenesis of vascular atherosclero-
sis. A number of studies have been performed to explore 
the effects of pharmacological inhibitors on VSMC prolifera-
tion and migration (Andres and Castro, 2003).  
Berberine is an isoquinoline alkaloid that has been iso-
lated from Berberis aquifolium (Oregon grape), Berberis 
aristata (tree turmeric), Berberis vulgaris (barberry), and 
Hydrastis canadensis (goldenseal). It has antibiotic (Stermitz 
et al., 2000), antitumor (Iizuka et al., 2003) and antidiar-
rheal (Choi et al., 2003) activities. It also appears to have 
effects on cardiovascular diseases, such as arrhythmia,  
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congestive heart failure, hypertension, and myocardial in-
farction (Lau et al., 2001). It is, however, still unclear 
whether berberine directly inhibits lysoPC-induced VSMC 
proliferation and migration, and what mechanisms are 
involved in these responses in vitro. Since many cell pro-
liferation factors, including various mitogens, initiate 
similar signaling events such as MAP kinase activation, 
we hypothesized that berberine might affect MAP kinase 
activation in response to lysoPC. In the present study, we 
tested this idea and sought to identify potential mecha-
nisms underlying the effect. 
 
 
Materials and Methods 
 
Cell culture VSMCs were isolated as previously described (Gun-
ther et al., 1982). Briefly, aortas were enzymatically isolated from 
the thoraxes of 8 week-old Sprague-Dawley rats. They were trans-
ferred to a plastic tube containing 5 ml of the enzyme dissociation 
mixture and incubated for 2 h at 37°C. The suspension was centri-
fuged at 1,000 × g for 10 min and the pellet resuspended in Dul-
becco’s modified Eagle’s medium (DMEM) with 10% fetal bo-
vine serum (FBS). The cells were maintained in DMEM supple-
mented with 10% FBS, 100 U/ml penicillin, 100 µg/ml strepto-
mycin in 75-cm2 flasks at 37°C in a humidified atmosphere of 
95% air and 5% CO2. All experiments were conducted using 
VSMCs between passages 7 and 15, after growth arrest by 
incubation in DMEM containing 0.5% FBS for 48 h. 
 
[
3
H]-Thymidine incorporation To evaluate DNA synthesis, 
thymidine incorporation assays were performed. VSMCs were 
plated in 24-well plates at 2 × 104 cells/ml. The cells were main-
tained for 24 h in medium containing 0.5% serum, and then 
treated with lysoPC after incubation with or without berberine 
for 1 h. After 24 h, 2 µCi/ml of [3H]-thymidine was added for 2 
h. The cells were then washed three times with ice-cold PBS, 
incubated for 30 min in 10% trichloroacetic acid on ice, washed 
twice in ice-cold 95% ethanol, and lysed in 0.2 N NaOH. Sam-
ples were measured by liquid scintillation counter. Data are 
expressed as percentages of the radioactivity measured under 
basal conditions. 
 
MTT assay To measure cell viability and proliferation, we used 
the MTT assay employing 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (Sigma, USA). VSMCs were 
seeded in 24-well culture plates at a concentration of 2 × 104 
cells/ml and treated with lysoPC after incubation with or with-
out berberine for 1 h. MTT solution (in PBS) was added to each 
well to a final concentration of 0.5 mg/ml and incubation con-
tinued in a humidified atmosphere at 37°C for 4 h, to allow 
MTT reduction. The formazan salt crystals were dissolved by 
adding dimethylsulfoxide (DMSO) and absorbances were meas-
ured at 570 nm with a microtiter plate reader. 
 
Cell migration assay VSMC migration was examined by a 
modified Boyden chamber assay with a Transwell cell culture 
chamber (Corning, USA), which allows cells to migrate through 
an 8-µm pore-size polycarbonate membrane (Law et al., 1996). 
Polycarbonate membranes with pores were coated with 10 
µg/well of gelatin solution in DMEM containing 0.5% FBS, and 
dried. VSMCs were suspended in DMEM with 0.5% FBS, pre-
treated with berberine for 1 h and seeded (2 × 104 cells/ml) into 
Transwell inserts. These were placed in a 24-well plate contain-
ing DMEM with 0.5% FBS, and migration was stimulated by 
adding lysoPC to the bottom well of the Boyden chamber. After 
12 h, the surfaces of the upper membranes were swabbed with 
cotton-tipped applicators to remove non-migrating cells, and the 
inserts were fixed in methanol for 30 min and stained with 1% 
crystal violet for 2 h. For quantitation, the cells on the surface of 
the upper membrane were removed with methanol. This allowed 
quantitative optical density analysis using a microtiter plate 
reader. 
 
Measurement of intracellular ROS intracellular ROS were 
measured in 24-well plates using 2′,7′-dichlorodihydrofluorescein 
diacetate (DCFH-DA), a cell-permeable, oxidation-sensitive 
probe (Tarpey and Fridovich, 2001). The dye is cleaved and 
trapped intracellularly, where it can be oxidatively modified by 
intracellular ROS and peroxidases to produce fluorescent 2′,7′-
dichlorofluorescein (DCF). Quiescent VSMCs were treated with 
lysoPC for 7 min after exposure to different berberine concen-
trations for 30 min, and then incubated with DCFH-DA for 7 
min. The medium was removed, the cells were washed twice 
with PBS, and samples resuspended in PBS were analyzed by 
flow cytometry at 488 nm excitation, 535 nm emission. 
 
SDS-PAGE and Western blot analysis After appropriate 
treatment, cells were rinsed with cold PBS, scraped into 1.5 ml 
tubes and solubilized in lysis buffer (20 mM Tris-Cl, pH 7.5, 
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 
mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM 
Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 
and 1 µg/ml leupeptin), followed by centrifugation at 12,000 × g 
for 20 min at 4°C. The protein concentrations in the super-
natants were determined with a Bradford protein assay kit (Bio-
Rad, USA). Cell lysates containing equal amounts of protein 
were subjected to SDS-polyacrylamide gel electrophoresis, and 
the proteins transferred to polyvinylidene difluoride (PVDF) 
membranes (Millipore, USA). After blocking in 10 mM Tris-Cl 
buffer (pH 8.0) containing 150 mM sodium chloride, 0.1% 
Tween 20, and 5% (w/v) non-fat dry milk, the membranes were 
treated with primary antibodies, followed by appropriate horse-
radish peroxidase-conjugated secondary antibodies. The anti-
gen-antibody bands were detected with an enhanced chemilumi-
nescence kit (Amersham Bioscience, Sweden), and quantified 
by densitometry. 
 
ERK1/2 activity assay ERK1/2 activity was assayed following 
the instructions with the commercial assay kit (Cell Signaling, 
USA). Briefly, cells were harvested with lysis buffer supplied by  
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Fig. 1. Effect of berberine on lysoPC-induced DNA synthesis 
(A) and cell proliferation (B) in VSMCs. A. Quiescent cells 
were pretreated with different concentrations of berberine for 1 
h. The cells were then stimulated with lysoPC (10 µM) for 24 h 
with [3H]-thymidine present for the final 2 h. B. Quiescent cells 
were pretreated with berberine for 1 h and incubated with 10 
µM of lysoPC for 48 h. Cell viability was quantified by the 
MTT assay. The results represent means ± SEM of three repli-
cate measurements in three separate experiments. 
 
 
the manufacturers and centrifuged at 12,000 × g for 10 min at 
4°C. The cell lysates were incubated overnight at 4°C with 20 µl 
of an immobilized dual phospho-specific ERK1/2 monoclonal 
antibody, and washed twice with lysis buffer and kinase buffer. 
The kinase reactions were performed in the presence of 200 µM 
ATP and Elk-1 protein at 30°C for 20 min and terminated with 
25 µl of SDS-loading buffer. Phosphorylation of Elk-1 was 
measured by Western blot analysis using antibody against phos-
pho-Elk-1 (Ser383) and the LumiGLO system supplied by the 
manufacturer. 
 
Luciferase reporter assay VSMCs were plated on 35-mm 
dishes and transfected with a luciferase reporter construct pos-
sessing consensus AP-1 binding sites (pAP1-Luc) (BD Biosci-
ences, USA). After incubation for 12 h, the medium was ex-
changed for fresh DMEM, and the cells were further incubated 
for 24 h. The VSMCs were then treated with lysoPC after incu-
bation with or without berberine for 1 h, harvested and 
luciferase activities measured with a luciferase reporter assay kit 
(BD Biosciences, USA) and a luminescence spectrophotometer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Effect of berberine on lysoPC-induced VSMC migration. 
VSMCs were pretreated with 10 µM of berberine for 1 h and 
seeded into Transwell inserts that were placed in a 24-well plate. 
LysoPC (10 µM) was added to the bottom of each well. After 12 
h, cells that migrated to the other side of the membrane were 
stained with 1% crystal violet and eluted with methanol, and 
quantitative analyses were performed by optical density meas-
urement using a microtiter plate reader. The results represent the 
means ± SEM of three different experiments. 
 
 
Specific luciferase activities were normalized for transfection 
efficiency using the corresponding β-galactosidase activities, 
and expressed as activities relative to the control. 
 
Statistical analysis Data are expressed as means ± S.E.M. Sta-
tistical comparisons were performed by one-way analysis of 
variance and Student’s t-test. Differences were considered sig-
nificant at P < 0.05. 
 
 
Results 
 
Inhibitory effect of berberine on lysoPC-induced cell 
proliferation We examined the effect of berberine on 
lysoPC-induced DNA synthesis in VSMCs, by measuring 
[3H]-thymidine incorporation. 24 h of lysoPC treatment 
(10 µM) increased DNA synthesis about 2.2-fold (Fig. 
1A), and pretreatment of the cells with berberine (0.1−100 
µM) inhibited this lysoPC-induced DNA synthesis in a 
concentration-dependent manner (Fig. 1A). Berberine 
also inhibited lysoPC-induced proliferation of VSMCs  
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Fig. 3. Effect of berberine on activation of ERK1/2 by lysoPC. 
Quiescent VSMCs were treated with different concentration of 
berberine for 1 h and stimulated with lysoPC (10 µM) for 15 
min. A. Equal amounts of protein were separated by SDS-PAGE 
and analyzed by Western blotting. Phosphorylation of ERK1/2 
was detected using a phospho-specific ERK1/2 antibody. Blots 
are representative of three experiments, all with similar results. 
B. Cells were lysed and equal amounts of extracted protein were 
immunoprecipitated with phospho-specific ERK1/2 antibody. 
Samples were then incubated with an Elk-1 protein in the pres-
ence of ATP. Phosphorylation of Elk-1 was measured by West-
ern blotting using phospho-Elk-1 (Ser383) antibody. Signals 
were quantified by scanning densitometry and the graph shows 
relative activities. The results represent the means ± SEM of 
three different experiments. 
 
 
(Fig. 1B). Since DNA synthesis was reduced to approxi-
mately the control level by 10 µM beberine, we used this 
concentration in subsequent experiments. 
 
Effect of berberine on lysoPC-induced cell migration 
The effect of berberine on lysoPC-induced VSMC migra-
tion was examined with a modified Boyden chamber as-
say. Treatment of VSMCs for 12 h with lysoPC induced a 
nearly 2-fold increase in the number of migrating cells 
and berberine inhibited this effect (Fig. 2).  
 
Effect of berberine on lysoPC-induced ERK1/2 activa-
tion We tested whether berberine inhibited the phosphoryla-
tion of ERK1/2 (Yamakawa et al., 2002) in lysoPC-
stimulated VSMCs. ERK1/2 phosphorylation increased in 
response to 15 min incubation with  lysoPC after serum 
starvation, and pretreatment with berberine was inhibitory 
(Fig. 3A). The levels of ERK1/2 protein were not affected 
by the treatment with berberine. We also tested whether 
the inhibition of ERK1/2 phosphorylation by berberine 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Effect of berberine on AP-1 activity induced by lysoPC. 
VSMCs transfected with pAP1-Luc were incubated for 24 h 
with lysoPC in the presence or absence of berberine (10 µM). 
Luciferase activity is expressed as activity relative to the un-
treated group (control). The results represent the means ± SEM 
of three different experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Effect of berberine on intracellular ROS formation in-
duced by lysoPC. After incubation with or without berberine for 
30 min, VSMCs were stimulated with 10 µM of lysoPC for 7 
min. Results are representative of at least three independent 
experiments with similar results. 
 
 
was paralleled by an effect on ERK1/2 activity. ERK1/2 
activity was analyzed by immunoprecipitation with an im-
mobilized ERK1/2 antibody followed by in vitro kinase 
assay with an Elk-1 fusion protein as substrate for ERK1/2. 
As shown in Fig. 3B, lysoPC stimulated ERK1/2 activity 
and this effect was inhibited by pretreatment with berberine 
in a manner paralleling the results of the Western blot 
analysis. Since ERK1/2 activation stimulates AP-1 activity 
(Kim and Iwao, 2003) we assessed the effect of berberine 
on lysoPC-induced AP-1 activity by means of a reporter 
assay (see Materials and Methods). Berberine pretreat-
ment inhibited the increase in AP-1-mediated reporter ac-
tivity induced by lysoPC (Fig. 4). 
 
Inhibitory effect of berberine on intracellular ROS 
generation Stimulation of vascular cells with lysoPC 
causes an increase in ROS (Kugiyama et al., 1999; Ya-
makawa et al., 2002). We tested whether berberine pre-
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vented lysoPC-induced ROS generation. Figure 5 shows 
that berberine reduced the formation of ROS in response 
to lysoPC. 
 
 
Discussion 
 
Proliferation of VSMCs has been implicated as one cause 
of atherosclerosis and post-intervention restenosis (Cho et 
al., 2005; Rivard and Andres, 2000). Hence many thera-
peutic approaches attempt to inhibit VSMC proliferation 
and migration (Andres and Castro, 2003). Oxidized LDL 
plays a pivotal role in the initiation and progression of 
atherosclerosis by affecting the activities of VSMCs, en-
dothelial cells and monocytes. LysoPC, an active compo-
nent of oxidized LDL, induces VSMC proliferation and 
migration (Kohno et al., 1998, and see above). We have 
demonstrated that berberine, a natural product, inhibits 
this VSMC proliferation and migration. LysoPC is mito-
genic and can activate ERK1/2 (Yamakawa et al., 1998) 
and regulate contraction of VSMCs (Della Rocca et al., 
1997). ERK1/2, is a member of the serine/threonine 
kinase family, which is activated by a variety of stimuli 
involved in cell growth, as well as by endogenously gen-
erated ROS in VSMCs stimulated with lysoPC (Ya-
makawa et al., 2002).  
Recent studies have demonstrated that statin treatment 
can inhibit the proliferation and migration of VSMCs 
(Takemoto and Liao, 2001). In addition, pitavastatin sup-
presses lysoPC-induced VSMC proliferation by inactivat-
ing the ERK1/2 pathway (Yamakawa et al., 2003). These 
results provide further support for the beneficial effect of 
cholesterol-lowering drugs, such as statins, on arterial 
walls. Recently Kong et al. identified berberine as a novel 
cholesterol-lowering drug with an action mechanism, i.e. 
increasing hepatic LDL receptors, different from that of 
statins (Kong et al., 2004). Berberine is known to have 
antibiotic, antitumor, and anti-hyperglycemic activities. 
However, it was not known whether berberine inhibited 
cell proliferation, migration and ERK1/2 activation in 
VSMCs. In our study, berberine inhibited lysoPC-induced 
VSMC proliferation and migration in a dose-dependent 
manner. Moreover, it also reduced the activation of ERK1/2 
and AP-1 by lysoPC. Therefore, it appears that berberine 
inhibits the proliferation and migration of VSMCs by 
suppressing the ERK1/2-AP-1 pathways. 
ROS play a key role in VSMC proliferation, which is 
important in the pathogenesis of atherosclerosis, hyper-
tension and restenosis after percutaneous coronary inter-
vention (Chen et al., 2003). Stimulation of VSMCs with 
lysoPC causes an increase in intracellular ROS and acti-
vates ERK1/2 (Yamakawa et al., 2002). ERK1/2 activa-
tion by lysoPC is inhibited by antioxidants such as N-
acetylcysteine, reduced glutathione monoester and vita-
min E (Watanabe et al., 2002; Yamakawa et al., 2002). 
Moreover berberine decreased ROS levels and inhibited 
angiogenesis in embryoid bodies, indicating that the com-
pound was acting as a scavenger of intracellular free radi-
cals (Wartenberg et al., 2003). Our data confirm that ber-
berine reduces intracellular ROS formation. It is, there-
fore, possible that the inhibitory effects of berberine on 
VSMC proliferation and migration result from its ability 
to inhibit activation of ERK1/2 by reducing ROS produc-
tion in response to lysoPC.  
Interestingly, clinical trials and animal studies have 
demonstrated that berberine prevents congestive heart 
failure (Zeng et al., 2003), cardiac hypertrophy (Hong et 
al., 2002) and arrhythmia (Lau et al., 2001). It also inhib-
its COX-2 expression by inhibiting AP-1, a key transcrip-
tion factor in inflammation and carcinogenesis (Kuo et 
al., 2004). Moreover, in an animal model, berberine was 
also shown to have vasodilator (Ko et al., 2000) and hy-
potensive (Kang et al., 2002) effects, based on its modula-
tion of K+ channel activity and inhibition of angiotensin-
converting enzyme activity, respectively. Indeed berberine 
may have multiple effects on the cardiovascular system. 
These include decreasing plasma cholesterol, reducing 
vascular inflammation, enhancing endothelial function, 
and inhibiting VSMC proliferation. Its antiproliferative 
effect on VSMCs may contribute to its long-term benefi-
cial effects on vascular walls, and its inhibitory action on 
MAP kinases, whose activation is dependent on intracel-
lular ROS, may play an important role in the direct cellu-
lar effects of berberine on vascular walls.  
In conclusion, our results demonstrate that berberine 
inhibits stimulation of VSMC proliferation and migration 
by lysoPC. Furthermore, the antiproliferative effect of 
berberine is mediated by inhibition of the ERK1/2 path-
way, and may be attributed to blocking the production of 
ROS. These findings help to clarify the clinical benefits 
of berberine and provide a scientific rationale for its use 
in cardiovascular diseases such as atherosclerosis and 
arterial restenosis. 
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